Transcend joining @Novartis Alcon tops OIS News in Feb : Eye on Five ois.net/eye-on-five-february… via @oistweets
Check out our CMO, Sean Ianchulev, presenting at last year's OIS meeting at AAO in Las Vegas @OISTWEETS @aao_ophth ois.net/transcend-aao-2015/
Thx @canaanpartners, @WendeHutton, & all our investors for your support of the CyPass #glaucoma therapy mddionline.com/blog/deviceta… @MDDIonline
Transcend is proud to announce we will be joining @Novartis #Alcon, world leader in eye care. novartis.com/news/media-rele… #glaucoma #MIGS
What do #glaucoma and other blinding conditions really look like? Check out medicaldaily.com/visual-impa… via @medicaldaily
MIGS in the suprachoroidal space: three reasons why it has a bright future @DrHovanesian @Healio_OSN healio.com/ophthalmology/gla…
Transcend Medical retweeted
Transcend @TranscendMed announced it had submitted the final module of its PMA application - buff.ly/1in5txU
Sean Ianchulev MD describes the potential of supraciliary microstenting with the CyPass Micro-Stent #MIGS #glaucoma ophthalmologytimes.modernmed…
CyPass AJO article on DUETTE study (multicenter trial on standalone procedure) covered in recent @Healio_OSN! goo.gl/4cmytp
Transcend is proud to be featured on the latest OIS podcast. ois.net/transcend-medical-re… via @oistweets
CyPass Micro-Stent US-IDE pivotal study positive; next glaucoma stent to file PMA with FDA late 2015. transcendmedical.com/intl/in…
Transcend Medical retweeted
VP of @TranscendMed gives his opinon on the OIS meetings buff.ly/1EuIZnx courtesy of @EWNews #Ophthalmology #Innovation
Transcend Medical retweeted
#Glaucoma runs in families. Ask your family about their eye health.
Our favorite CEO Brian Walsh & the CyPass Micro-Stent "transcending glaucoma treatment" featured in @MassDevice! massdevice.com/features/bria…
Transcend Medical retweeted
.@TranscendMed Raises $22M Series C to transform the treatment of glaucoma. fb.me/2bEQj5U9D
Transcend Medical retweeted
Transcend Medical closes on $22M Series C round | MassDevice massdevice.com/news/transcen…
We are proud to announce the closing of a $22M Series C financing to help us complete the COMPASS U.S. pivotal study! marketwired.com/press-releas…
Our CMO, Dr. Sean Ianchulev, speaking at @GlaucomaOrg @PalaceHotelSF with a CyPass Micro-Stent update. Nice job Sean!
2-year CyPass Micro-Stent data from our European study, published in the Ophthalmology Times, and featuring our... fb.me/YwYURYRS
2-year European data on the CyPass Micro-Stent MIGS implant for glaucoma featured in @OphthTimes shar.es/UBqth







